| ²é¿´: 504 | »Ø¸´: 0 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
zhangyong8107ľ³æ (СÓÐÃûÆø)
|
[½»Á÷]
¶¡ÂÝ»·ÍªÓëÅÁÂÞÎ÷Í¡ÁªºÏÖÎÁÆÒÖÓôÖ¢µÄÁÙ´²Ñо¿
|
||
|
¡¾ÕªÒª¡¿ Ä¿µÄ ̽ÌÖ¶¡ÂÝ»·ÍªÓëÅÁÂÞÎ÷Í¡ÁªºÏÖÎÁÆÒÖÓôÖ¢µÄÁÆÐ§¡£ ·½·¨ ·ûºÏICD-10»òCCMD-3ÒÖÓôÖ¢µÄÕï¶Ï±ê×¼µÄÃÅÕïºÍסԺ²¡ÈË79Àý£¬Ëæ»ú·Ö³ÉÁ½×飬·Ö±ðÓö¡ÂÝ»·ÍªÁªºÏÅÁÂÞÎ÷Í¡ºÍµ¥ÓÃÅÁÂÞÎ÷Í¡ÖÎÁÆ6ÖÜ£¬²ÉÓúºÃܶû¶ÙÒÖÓôÁ¿±í£¨HAMD£©¡¢ººÃܶû¶Ù½¹ÂÇÁ¿±í£¨HAMA£©ÆÀ¶¨ÁÆÐ§£¬Óø±·´Ó¦Á¿±í£¨TESS£©ÆÀ¶¨¸±·´Ó¦¡£ ½á¹û 6ÖÜÄ©ÁªºÏ×éHAMDºÍHAMAÆÀ·ÖµÍÓÚµ¥ÓÃ×é¡£ÔÚµÚ2ÖÜÄ©¡¢µÚ6ÖÜÄ©ÁªºÏ×éµÄHAMDºÍHAMAµÄƽ¾ù¼õ·ÖÂʸßÓÚµ¥ÓÃ×é¡£Á½×é¼äµÄ¸±·´Ó¦Çé¿öÏà·Â¡£ ½áÂÛ ¶¡ÂÝ»·ÍªÁªºÏÅÁÂÞÎ÷Í¡ÖÎÁÆÒÖÓôÖ¢µÄÁÆÐ§ÓÅÓÚµ¥ÓÃÅÁÂÞÎ÷Í¡¡£ ¡¡¡¡¡¾¹Ø¼ü´Ê¡¿ ¶¡ÂÝ»·Íª£» ÅÁÂÞÎ÷Í¡£» ÒÖÓôÖ¢ ¡¡¡¡A comparative study of buspirone mixed paroxetine in the treatment of depression ¡¡¡¡LIN Zhao-wu, SUN Guo-ping. Qingdao Mental Health Center, Shandong 266034,China. ¡¡¡¡¡¾Abstract¡¿ Objective To study the efficacy of buspirone mixed paroxetine on depression.Methods 79 cases of outpatients and inpatients with the depression diagnosed according to ICD-10 or CCMD-3 were divided into two groups randomly. The two groups were treated with buspirone mixed paroxetine and single paroxetine respectively for six weeks. The efficacy was measured with Hamiltion Depression Scale (HAMD) and Hamiltion Anxiety Scale (HAMA). The side effects were assessed by the Treatment Emergent Symptom Scale(TESS).Results The HAMD and HAMA scale in buspirone mixed paroxetine therapy group was significantly lower than single paroxetine group on six weekend. The reduce rate of mean score of HAMA and HAMD in combined group was significantly higher than single group. Two groups of side effects was similar. Conclusion Buspirone mixed paroxetine therapy was better effect in treatment of depression. ¡¡¡¡¡¾Key words¡¿ buspirone; paroxetine; depression ¡¡¡¡¶¡ÂÝ»·ÍªÊÇÒ»ÖÖÐÂÐÍ¿¹½¹ÂÇÒ©£¬ÁÙ´²ÉÏÒÑÓÃÓڹ㷺½¹ÂÇÖ¢£Û1£¬2£ÝºÍ°éÒÖÓôÖ¢×´¡¢½¹ÂÇÖ¢×´µÄÆäËû¼²²¡µÄÖÎÁÆ£Û3£Ý¡£¹úÍâÓв»ÉÙ±¨µÀÈÏΪ¸ÃÒ©¶ÔÒÖÓôÖ¢ÒàÓнϺÃÁÆÐ§£Û4£¬5£Ý¡£±¾ÎÄ̽ÌÖ¶¡ÂÝ»·ÍªÓëÅÁÂÞÎ÷Í¡ÁªºÏÖÎÁÆÒÖÓôÖ¢µÄÁÆÐ§¡£ ¡¡¡¡1 ×ÊÁÏÓë·½·¨ ¡¡¡¡1£®1 Ò»°ã×ÊÁÏ Ñо¿¶ÔÏóÀ´Ô´ÓÚÇൺÊо«ÉñÎÀÉúÖÐÐÄ2004Äê3Ô¡«2004Äê8ÔµÄÃÅÕïºÍסԺ²¡ÈË£¬Èë×é±ê×¼:ÄêÁä15¡«65Ë꣬·ûºÏICD-10»òCCMD-3ÒÖÓôÖ¢µÄÕï¶Ï±ê×¼£¬HamiltonÒÖÓôÁ¿±í£¨HAMD£©ÆÀ¶¨18·ÖÒÔÉÏ¡£ÅųýÓÐÑÏÖØÐÄÄÔѪ¹Ü¼²²¡¡¢¸ÎÉö¼²²¡µÈÑÏÖØÇûÌå¼²²¡µÄ»¼Õß¡£¹²79Àý£¬Ëæ»ú·Ö³ÉÁ½×飬һ×éΪ¶¡ÂÝ»·ÍªÓëÅÁÂÞÎ÷Í¡ÁªºÏÖÎÁÆ×飨ÁªºÏ×飩40Àý£¬ÄÐ20Àý£¬Å®20Àý£¬Æ½¾ùÄêÁ䣨46.97¡À12.10£©Ë꣬ƽ¾ù²¡³Ì£¨32.27¡À64.87£©Ì죻һ×éΪÅÁÂÞÎ÷Í¡ÖÎÁÆ×飨µ¥ÓÃ×飩39Àý£¬ÄÐ19Àý£¬Å®20Àý£¬Æ½¾ùÄêÁ䣨42.56¡À15.71£©Ë꣬ƽ¾ù²¡³Ì£¨37.06¡À53.24£©Ìì¡£ÒÔÉϸ÷ÏîÁ½×é¼ä²îÒì¾ùÎÞÏÔÖøÐÔ£¨P>0.05£©¡£ ¡¡¡¡1.2 ·½·¨ Á½×éÒ©ÎïÇåÏ´ÆÚ¾ùΪ1ÖÜ£¬ÁªºÏ×鏸Óè¶¡ÂÝ»·Íª¹Ì¶¨¼ÁÁ¿30mgºÍÅÁÂÞÎ÷Í¡¹Ì¶¨¼ÁÁ¿20mg£¬µ¥ÓÃ×鏸ÓèÅÁÂÞÎ÷Í¡¹Ì¶¨¼ÁÁ¿20mg/d£¬ÁƳÌΪ6ÖÜ£¬ÖÎÁÆÆÚ¼ä²»µÃºÏ²¢°²¶¨ÀàÒ©Îï¡£Á½×éÔÚÈë×éǰºÍÈë×éºóµÚ1¡¢2¡¢4¡¢6ÖÜ£¬·Ö±ðÓÃHAMD¡¢HAMA¡¢CGI¡¢TESSÁ¿±íÆÀ·Ö£¬ÔÚÖÎÁÆÇ°ºÍÖÎÁƺó½øÐÐѪ¡¢Äò³£¹æ¡¢ÑªÉú»¯ºÍÐĵçͼ¼ì²é¡£ ¡¡¡¡1.3 ÁÆÐ§±ê×¼ HAMD¼õ·ÖÂÊ¡Ý75%ΪȬÓú£¬¡Ý50%ΪÏÔÖø½ø²½£¬¡Ý25%Ϊ½ø²½£¬£¼25%ΪÎÞЧ¡£ ¡¡¡¡1.4 ͳ¼ÆÑ§·½·¨ ËùÓÐ×ÊÁÏÓ¦ÓÃSPSSÈí¼þ½øÐÐͳ¼Æ·ÖÎö¡£ ¡¡¡¡2 ½á¹û ¡¡¡¡2£®1 ÁÙ´²ÁÆÐ§ ÁªºÏ×éºÍµ¥ÓÃ×é¾ùÔÚÖÎÁƵÚ2ÖÜÄ©HAMDƽ¾ù¼õ·ÖÂÊ>25%£¬´ïµ½½ø²½£»µÚ6ÖÜĩƽ¾ù¼õ·ÖÂÊ>50%´ïµ½ÏÔÖø½ø²½¡£µÚ6ÖÜÄ©ÁªºÏ×éHAMDºÍHAMA ÆÀ·ÖµÍÓÚµ¥ÓÃ×飬²îÒìÓÐÏÔÖøÐÔ£¨P<0.05£©£»ÔÚµÚ2ÖÜÄ©ÁªºÏ×éµÄHAMDºÍHAMAµÄƽ¾ù¼õ·ÖÂʸßÓÚµ¥ÓÃ×飬²îÒìÓÐÏÔÖøÐÔ£¨P<0.05£©£¬ÔÚµÚ6ÖÜÄ©ÁªºÏ×éµÄHAMDºÍHAMAµÄƽ¾ù¼õ·ÖÂÊÃ÷ÏÔ¸ßÓÚµ¥ÓÃ×飬²îÒìÓзdz£ÏÔÖøÐÔ£¨P<0.01£©£¬¼û±í1¡¢2¡£±í1 ÁªºÏ×éÓëµ¥ÓÃ×éÖÎÁÆÇ°ºóHAMDºÍHAMAÆÀ·Ö±È½Ï ×¢£º*P<0.05±í2 ÁªºÏ×éÓëµ¥ÓÃ×éÖÎÁÆÇ°ºóHAMDºÍHAMAÆÀ·Ö¼õ·ÖÂÊ±È½Ï ×¢£º*P<0.05£¬**P<0.01 ¡¡¡¡2.2 ²»Á¼·´Ó¦·ÖÎö ÖÎÁƽáÊøÊ±ÁªºÏ×éTESSÆÀ·ÖΪ£¨2.61¡À1.50£©·Ö£¬µ¥ÓÃ×éΪ£¨2.31¡À1.18£©·Ö,Á½×é¼ä²îÒìÎÞÏÔÖøÐÔ£¨P>0.05£©¡£ÁªºÏ×鸱·´Ó¦ÓÐÍ·ÔΡ¢¶ñÐÄ¡¢±ãÃØºÍʧÃߣ»µ¥ÓÃ×éÒÔ¶ñÐÄ¡¢±ãÃØºÍ½¹ÂÇΪ¶à¡£¼û±í3¡£±í3 Á½×é²»Á¼·´Ó¦µÄ³öÏÖÆµ¶È ¡¡¡¡3 ÌÖÂÛ ¡¡¡¡¶¡ÂÝ»·Íª¶Ô5-HT1AÊÜÌåÓÐÑ¡ÔñÐÔÇ׺ÍÁ¦£¬±íÏÖ³öÁ½ÖÖ×÷Ó᪡ªÍêÈ«µÄÍ»´¥Ç°¼¤¶¯¼Á¹¦ÄܺͲ¿·ÖÍ»´¥ºó¼¤¶¯¼Á¹¦ÄÜ£Û4£Ý£¬ÓÉ´ËÍÆ²â£ºÐ¡¼ÁÁ¿Ê¹Óö¡ÂÝ»·ÍªÊ±£¬Í»´¥Ç°5-HT1A×ÔÉíÊÜÌ弤¶¯×÷ÓôóÓÚÍ»´¥ºó5-HT1AÊÜÌ弤¶¯×÷Óã¬Òò¶ø²úÉú¸º·´À¡ÒÖÖÆ×÷Óã¬Ê¹½¹ÂÇÖ¢¹ý¸ßµÄ5-HT»îÁ¦½µµÍ£¬»º½â½¹ÂÇÖ¢×´£»¶ø´ó¼ÁÁ¿Ê¹Óö¡ÂÝ»·Íªºó£¬µ¼Ö¸º·´À¡ÒÖÖÆ×÷ÓüõÉÙ£¬Ê¹Í»´¥ºó¼¤¶¯×÷ÓÃÔöÇ¿£¬Ïà¶ÔµØÌá¸ßÁË5-HTÉñ¾µÝÖʻ£¬´Ó¶ø²úÉú¿¹ÒÖÓô×÷ÓãÛ6£Ý¡£±¾Ñо¿½á¹û±íÃ÷ÅÁÂÞÎ÷Í¡ÁªºÏ¶¡ÂÝ»·ÍªÖÎÁÆÒÖÓôÖ¢µÄÁÆÐ§ÒªºÃÓÚµ¥ÓÃÅÁÂÞÎ÷Í¡ÖÎÁƵÄÁÆÐ§£¬Óë¹úÄÚÍâµÄ±¨µÀÏàÒ»Ö£Û7£¬8£Ý¡£Õâ³ýÁËÓë¶¡ÂÝ»·Íª±¾ÉíÓп¹ÒÖÓô×÷ÓÃÓйØÒÔÍ⣬»¹Ö÷ÒªÒòΪ¶¡ÂÝ»·Íª¶Ô¿¹ÒÖÓô¼ÁÓÐÔöЧ×÷ÓãÛ7£Ý¡£ ¡¡¡¡±¾Ñо¿Í¬Ê±·¢ÏÖÁªºÏµÚ2ÖÜÄ©HAMDºÍHAMAµÄ¼õ·ÖÂÊÒÑ´óÓÚÅÁÂÞÎ÷Í¡×飬Õâ¿ÉÄÜÓë¶¡ÂÝ»·Íª¿¹½¹ÂÇ×÷ÓÃÓйأ¬ËüÊ×ÏȸÄÉÆÁ˲¡È˵Ľ¹ÂÇÖ¢×´£»Æä´Î£¬×èÖÍÖ¢×´»º½â½ÏÂý£Û9£Ý¡£Â½ï£µÈ£Û3£Ý·¢ÏÖ£º¾¡¹ÜËæ×ÅHAMAÏÔÖø¼õÉÙ£¬HAMDÒ²ÔÚ2ÖܺóÓëÖÎÁÆÇ°¶Ô±È·¢ÉúÏÔÖøÐÔ²îÒ죬µ«ÒÖÓôµÄºËÐÄÖ¢×´¡ª¡ª×èÖÍÖ¢×´¡ª¡ª²¢Î´Ñ¸ËÙ»º½â£¬¶øÊǾ¹ý4Öܺó²ÅÏÔÖø¼õ·Ö£¬ËµÃ÷»¼ÕßµÄÒÖÓô֢״ûÓÐËæ×Ž¹ÂǵĿØÖƶø×ÔÈ»»º½â£¬ÕâÓë±¾ÎĽá¹ûÏàÒ»Ö¡£Á½×鲡ÈËÔÚÖÎÁƵĵÚ4ÖÜÒòΪÒÖÓôµÄºËÐÄÖ¢×´¿ÉÄܼÌÐø´æÔÚ£¬HAMDµÄ¼õ·ÖÂʲîÒìÎÞÏÔÖøÐÔ£»µ«ÊÇÔÚµÚ6ÖÜÓÉÓÚ¶¡ÂÝ»·ÍªµÄ¿¹ÒÖÓô×÷Ó㬻òÕßÊǶÔÅÁÂÞÎ÷Í¡µÄÔöЧ×÷Óã¬ÏÔʾÁËÁªºÏÖÎÁƵÄÁ¼ºÃÁÆÐ§¡£ ¡¡¡¡Óö¡ÂÝ»·ÍªÖÎÁƵIJ¡ÈËÔ¼67%¡«88%δ³öÏÖÈκβ»Á¼·´Ó¦£¬¸±·´Ó¦½ÏÉÙ½ÏÇᣬÖ÷ÒªÓУºÍ·ÔΣ¨6.6%£©¡¢Í·Í´£¨4.9%£©£¬Î¸³¦¹¦ÄÜÎÉÂÒ£¨6.0%£©ºÍʧÃߣ¨3.8%£©¡£±¾Ñо¿·¢ÏÖ²¢Ã»ÓÐÒòΪºÏ²¢ÓÃÒ©£¬¶øÔö¼ÓÒ©ÎïµÄ¸±·´Ó¦£»ÁªºÏ×éÓÐ5Àý£¨15.2%£©³öÏÖ¶ñÐÄ£¬3Àý(9.09%)ÓÐÍ·ÔΣ¬3Àý£¨9.09%£©ÓбãÃØ£¬ÕâÓë÷ÆäÒ»µÈ£Û8,9£Ý±¨µÀµÄ½á¹û±È½ÏÒ»Ö¡£ ¡¡¡¡±¾Ñо¿½á¹û±íÃ÷£¬¶¡ÂÝ»·ÍªÁªºÏÅÁÂÞÎ÷Í¡ÖÎÁÆÒÖÓôÖ¢£¬¿ÉÄܼӿìÆðЧµÄʱ¼ä£¬ÓÈÆäÊǶ԰éÓÐÃ÷ÏÔ½¹ÂÇÖ¢µÄ»¼Õߣ¬ÄܲúÉú½ÏºÃµÄÖÎÁÆÐ§¹û¡£ ¡¡¡¡¡¾²Î¿¼ÎÄÏס¿ ¡¡¡¡1 ÖìÔ¾»ª.¶¡ÂÝ»·ÍªÖÎÁƹ㷺ÐÔ½¹ÂÇÖ¢ÁÙ´²¶ÔÕÕÑо¿.ÁÙ´²¾«ÉñҽѧÔÓÖ¾, 2000£¬1£º20. ¡¡¡¡2 ¿öÀû£¬ÑîµÂÀ¼£¬Áèºç.¶¡ÂÝ»·ÍªÖÎÁƹ㷺ÐÔ½¹ÂÇÖ¢µÄÏà¹ØÑо¿.ÖйúÉñ¾¾«Éñ¼²²¡ÔÓÖ¾£¬2001£¬27(4)£º295. ¡¡¡¡3 ½¬Ëï»Û·¼£¬Öܾý¸»£¬µÈ.¶¡ÂÝ»·ÍªÖÎÁưéÒÖÓôÖ¢×´½¹ÂÇÖ¢µÄÁÙ´²Ñо¿.ÉϺ£¾«Éñҽѧ£¬1999£¬2£º88. ¡¡¡¡4 Robinson DS. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis in the treatment of depression. J Clin Psychopharmacol, 1990, 10: 67-76. ¡¡¡¡5 Rickels K. Buspirone in major depression: a controlled study. J Clin Psychiatry, 1991,52(1): 34-38. ¡¡¡¡6 л±ó£¬Íõ׿³Ð.¿¹½¹ÂÇÐÂÒ©¡ª¶¡ÂÝ»·ÍªµÄÑо¿ÓëÓ¦ÓÃÏÖ×´.¹úÍâҽѧ¡¤¾«Éñ²¡Ñ§·Ö²á£¬1993£¬1£º20. ¡¡¡¡7 De Battista C, Sofuoglu M,Schatzberg AF. Serotonergic synergism: The risk and benefits of combining the selective serotomin reuptake inhibitors with other serotonergic drugs. Biol Psychiatry, 1998,44: 34. ¡¡¡¡8 Stahl SM. Essential Psychopharmacology. Second Edition.Cambridge University Press£¬ 2000£¬273. ¡¡¡¡9 ÷ÆäÒ»£¬ÍõÏþÁú.¶¡ÂÝ»·Íª¿ª·ÅÖÎÁƽ¹ÂÇÖ¢19ÀýÁÙ´²·ÖÎö.ÁÙ´²¾«ÉñҽѧÔÓÖ¾£¬1998£¬6:332. ¡¡¡¡×÷Õßµ¥Î»£º 266034 ɽ¶«Çൺ£¬ÇൺÊо«ÉñÎÀÉúÖÐÐÄ |
» ²ÂÄãϲ»¶
ÇópubpeerÕ˺Å
ÒѾÓÐ3È˻ظ´
ÇóÖú£¬PCRÀ©Ôö²úÎïÓÐÁ½¸öÌõ´ø
ÒѾÓÐ1È˻ظ´
¿ÚÇ»Âò¢Ãæ¿ÆÑ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ145È˻ظ´
¹ã¶«Ò©¿Æ´óѧÖÐҩѧԺ˶ʿÑо¿ÉúÕÐÉúµ÷¼Á
ÒѾÓÐ1È˻ظ´
ÇóÖúÂÛÎÄһƪ
ÒѾÓÐ2È˻ظ´
É¢½ð±ÒÆÚ´ý»ù½ðÁ¢Ïî
ÒѾÓÐ42È˻ظ´
ÆÀÉóÒâ¼û
ÒѾÓÐ6È˻ظ´
°²»Õũҵ´óѧÁÖѧԺ ÉÁÖ±£»¤Ñ§¡¢ÁÖÒµ£¨×¨Ë¶£©»¶ÓÓÐÖ¾Õßµ÷¼Á
ÒѾÓÐ0È˻ظ´














»Ø¸´´ËÂ¥